Tuesday, February 27, 2024
Follow us on :

Cancer Test Firm Guardant Health Posts Smaller Than Expected Q3 Loss, Lifts Annual Sales Outlook

Guardant Health Inc (NASDAQ: GH) reported Q3 revenue of $143 million, up 22% Y/Y, beating the consensus of $137.37 million.

Precision oncology revenue grew 31%, driven predominantly by increased clinical testing volume and biopharma sample volume, which grew 35% and 11%, respectively.

The company reported 43,900 tests to clinical customers and 7,500 tests to biopharmaceutical customers in the ...

Full story available on

Disclaimer: The views, recommendations, and opinions expressed in this content belong solely to the third-party experts. This site was not involved in the writing and production of this article.

Disclaimer Press Release Banner